• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.

作者信息

Patoulias Dimitrios, Papadopoulos Christodoulos, Boulmpou Aristi, Doumas Michael

机构信息

Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.

Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.

出版信息

Diabetes Obes Metab. 2021 Jul;23(7):1696-1700. doi: 10.1111/dom.14359. Epub 2021 Mar 12.

DOI:10.1111/dom.14359
PMID:33606909
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8014812/
Abstract
摘要

相似文献

1
Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.针对钠-葡萄糖协同转运蛋白2抑制剂引起呼吸道感染风险的标志性心血管和肾脏结局试验的荟萃分析：对2019冠状病毒病大流行的启示
Diabetes Obes Metab. 2021 Jul;23(7):1696-1700. doi: 10.1111/dom.14359. Epub 2021 Mar 12.
2
Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients with type 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic.长期使用钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者血浆容量状态的影响：COVID-19大流行期间一项前瞻性观察性研究的亚分析
Kardiol Pol. 2022;80(1):80-82. doi: 10.33963/KP.a2021.0160. Epub 2021 Nov 16.
3
Commentary: Mortality Risk of Antidiabetic Agents for Type 2 Diabetes With COVID-19: A Systematic Review and Meta-Analysis.评论：2型糖尿病合并新型冠状病毒肺炎患者使用抗糖尿病药物的死亡风险：一项系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2022 Jan 10;12:825100. doi: 10.3389/fendo.2021.825100. eCollection 2021.
4
Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials.在标志性心血管和肾脏结局试验中评估钠-葡萄糖协同转运蛋白2抑制剂导致截肢风险的最新荟萃分析。
Diabetes Obes Metab. 2021 Apr;23(4):1063-1065. doi: 10.1111/dom.14297. Epub 2020 Dec 29.
5
Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?2019冠状病毒病大流行时代的钠-葡萄糖协同转运蛋白2抑制剂：利弊比是否仍然有利？
J Diabetes Sci Technol. 2020 Jul;14(4):745-747. doi: 10.1177/1932296820932155. Epub 2020 Jun 2.
6
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂治疗 2 型糖尿病的药效学、疗效和安全性。
Drugs. 2015 Jan;75(1):33-59. doi: 10.1007/s40265-014-0337-y.
7
Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.钠-葡萄糖协同转运蛋白 2 抑制剂与 2 型糖尿病患者不良肾脏结局风险：一项随机对照试验的网络和累积荟萃分析。
Diabetes Obes Metab. 2017 Aug;19(8):1106-1115. doi: 10.1111/dom.12917. Epub 2017 Mar 31.
8
Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study.钠-葡萄糖协同转运蛋白 2 抑制剂与 COVID-19 易感性：一项基于人群的回顾性队列研究。
Diabetes Obes Metab. 2021 Jan;23(1):263-269. doi: 10.1111/dom.14203. Epub 2020 Oct 19.
9
SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.SGLT-2 抑制剂与感染风险：一项随机对照试验的系统评价和荟萃分析。
Acta Diabetol. 2018 May;55(5):503-514. doi: 10.1007/s00592-018-1116-0. Epub 2018 Feb 27.
10
Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂在 2 型糖尿病治疗中的最新进展：一种有价值的治疗工具。
Mini Rev Med Chem. 2020;20(3):170-182. doi: 10.2174/1389557519666191009163519.

引用本文的文献

1
The relationship between use of SGLT2is and incidence of respiratory and infectious diseases and site-specific fractures: a meta-analysis based on 32 large RCTs.基于 32 项大型 RCT 的荟萃分析：SGLT2is 的使用与呼吸道和传染病及特定部位骨折发生率的关系。
Eur J Clin Pharmacol. 2024 Apr;80(4):563-573. doi: 10.1007/s00228-024-03631-7. Epub 2024 Jan 25.
2
Noninsulin-based antihyperglycemic medications in patients with diabetes and COVID-19: A systematic review and meta-analysis.糖尿病合并 COVID-19 患者的非胰岛素类降糖药物：系统评价和荟萃分析。
J Diabetes. 2023 Feb;15(2):86-96. doi: 10.1111/1753-0407.13359. Epub 2023 Jan 23.
3
Non-Insulin Novel Antidiabetic Drugs Mechanisms in the Pathogenesis of COVID-19.新型非胰岛素类抗糖尿病药物在2019冠状病毒病发病机制中的作用机制
Biomedicines. 2022 Oct 19;10(10):2624. doi: 10.3390/biomedicines10102624.

本文引用的文献

1
Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.在新冠病毒检测呈阳性的糖尿病患者中，使用 GLP-1 受体激动剂、DPP-4 抑制剂或 SGLT-2 抑制剂的新冠病毒感染结局相似。
Diabetes Obes Metab. 2021 Jun;23(6):1397-1401. doi: 10.1111/dom.14329. Epub 2021 Feb 16.
2
DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials.二肽基肽酶-4抑制剂与呼吸道感染：心血管结局试验的系统评价和荟萃分析
Diabetes Care. 2021 Mar;44(3):e36-e37. doi: 10.2337/dc20-2018. Epub 2021 Jan 12.
3
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.达格列净对 COVID-19 导致呼吸衰竭患者主要临床事件预防和恢复的影响：DARE-19 研究的设计和原理。
Diabetes Obes Metab. 2021 Apr;23(4):886-896. doi: 10.1111/dom.14296. Epub 2021 Jan 19.
4
Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.2 型糖尿病患者因 COVID-19 住院与降糖药物相关的死亡率和其他不良结局：一项全国性队列研究。
BMC Med. 2020 Nov 16;18(1):359. doi: 10.1186/s12916-020-01832-2.
5
COVID-19 and diabetes mellitus: from pathophysiology to clinical management.新型冠状病毒肺炎与糖尿病：从病理生理学到临床管理。
Nat Rev Endocrinol. 2021 Jan;17(1):11-30. doi: 10.1038/s41574-020-00435-4. Epub 2020 Nov 13.
6
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
7
Anti-inflammatory properties of antidiabetic drugs: A "promised land" in the COVID-19 era?抗糖尿病药物的抗炎特性：COVID-19 时代的“希望之地”？
J Diabetes Complications. 2020 Dec;34(12):107723. doi: 10.1016/j.jdiacomp.2020.107723. Epub 2020 Aug 26.
8
Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study.1 型和 2 型糖尿病与英格兰 COVID-19 相关死亡率的关联：一项全人群研究。
Lancet Diabetes Endocrinol. 2020 Oct;8(10):813-822. doi: 10.1016/S2213-8587(20)30272-2. Epub 2020 Aug 13.
9
The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study.高血压和糖尿病药物治疗与新冠病毒疾病严重程度及免疫特征的关联：一项观察性研究。
Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):e48-e51. doi: 10.1093/ehjcvp/pvaa098.
10
Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies.钠-葡萄糖协同转运蛋白2抑制剂对内皮功能的影响：临床前研究的系统评价
Diabetes Ther. 2020 Sep;11(9):1947-1963. doi: 10.1007/s13300-020-00885-z. Epub 2020 Jul 27.